Hypertrophic Cardiomyopathy
A comprehensive guide to hypertrophic cardiomyopathy, obstruction, sudden-death risk, treatment and family screening.
Hypertrophic cardiomyopathy is a heart-muscle disease in which the ventricular wall is abnormally thickened without another condition fully explaining the degree of hypertrophy. It may obstruct blood flow from the left ventricle and can be associated with atrial fibrillation, heart failure or ventricular arrhythmias.
Diagnosis and Risk
Evaluation includes ECG and echocardiography, often supplemented by cardiac MRI, exercise testing and rhythm monitoring. Wall thickness, family history, unexplained fainting, ventricular arrhythmias, ventricular function, apical aneurysm and scar burden contribute to sudden-cardiac-death assessment. Genetic counselling can guide testing of relatives.
Treatment
Treatment is tailored to symptoms and physiology. Medicines may reduce heart rate and obstruction. Selected patients with persistent obstructive symptoms may be considered for myosin inhibitors, surgical myectomy or alcohol septal ablation in an experienced centre. An ICD is considered when the estimated arrhythmic risk justifies the benefits and device-related burdens.
Exercise advice and family screening should be individualised rather than based on a single measurement.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.